Original paper
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial.
Abstract
542 Background: Regorafenib significantly improved overall survival (OS) versus placebo in patients (pts) with uHCC who progressed on prior sorafenib therapy in the phase 3 RESORCE trial. The multicenter, international REFINE trial was designed to evaluate the safety and effectiveness of regorafenib in uHCC in the real-world setting. Methods: This prospective, observational trial aims to recruit 1000 pts with uHCC for whom a decision to treat...
Paper Details
Title
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial.
Published Date
Feb 1, 2020
Journal
Volume
38
Issue
4_suppl
Pages
542 - 542
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History